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Abstract
With an estimated 3% of the world’s population chronically infected, hepatitis C virus (HCV) represents a major health problem for which
an efﬁcient vaccination strategy would be highly desirable. Indeed, chronic hepatitis C is recognized as one of the major causes of cirrhosis,
hepatocarcinoma and liver failure worldwide and it is the most common indication for liver transplantation, accounting for 40–50% of liver
transplants. Much progress has been made in the prevention of HCV transmission and in therapeutic intervention. However, even if a new
wave of directly acting antivirals promise to overcome the problems of low efﬁcacy and adverse effects observed for the current standard of
care, which include interferon-a and ribavirin, an effective vaccine would be the only means to deﬁnitively eradicate infection and to diminish
the burden of HCV-related diseases at affordable costs. Although there is strong evidence that the goal of a prophylactic vaccine could be
achieved, there are huge development issues that have impeded reaching this goal and that still have to be addressed. In this article we
address the question of whether an HCV vaccine is needed, whether it will eventually be feasible, and why it is so difﬁcult to produce.
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Introduction
No vaccine for the prevention of hepatitis C virus (HCV)
infection is yet available. The current standards of care, based
on the combination of interferon-a (IFN-a), ribavirin (RBV)
and—for genotype 1 infections—NS3 protease inhibitors, still
have suboptimal rates of success, are burdened by consider-
able side effects, and are unlikely to be widely used because of
very high costs [1]. Given that HCV is responsible for a
substantial proportion of chronic liver diseases worldwide,
including cirrhosis and hepatocellular carcinoma, and that
more than 170 million people are infected [2], a prophylactic
vaccine represents an unmet medical need that would be of
great public health beneﬁt. Indeed, vaccination has proved to
be the most successful and cost-effective strategy to prevent
infections and associated diseases.
Among the difﬁculties that have hampered the development
of a vaccine against HCV there are its extreme genetic
variability, the lack of small animal models for testing vaccines,
and the fact that a cell culture system supporting the
production of infectious HCV and allowing studies on virus
neutralization in vitro became available only recently [3–5].
Despite these issues, much progress has been made toward
the identiﬁcation of promising prophylactic vaccine candidates,
and some of these candidate vaccines have entered clinical
trials. However, several issues concerning development and
efﬁcacy assessment of HCV vaccines remain to be addressed.
Should these be overcome, the control of HCV spread would
appear a realistic goal to achieve.
The Virus
Hepatitis C virus is a small, enveloped, single-stranded RNA
virus classiﬁed as a member of the Hepacivirus genus within the
Flaviviridae family [6]. The 9.6-kb positive-sense RNA genome
contains a single open reading frame encoding a polyprotein of
about 3000 amino acids, which, upon translation, is cleaved into
ten different structural (core and envelopes gpE1 and gpE2) and
non-structural (p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B)
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proteins [7]. An impressively high replication rate (1012 virions/
day) [8] and the lack of proof-reading activity by the viral
RNA-dependent RNA polymerase account for the high genetic
variability of the virus [9]. Seven major genotypes (with 30–35%
variability in nucleotide sequence) and many subtypes (15–20%
variability) have been distinguished phylogenetically. Moreover,
HCV circulates within an infected individual as distinct ‘quasi-
species’ [10].
Acute HCV infection is usually subclinical and 50–85% of
infected individuals develop chronic infection, a condition
leading to cirrhosis and, in some cases, to liver failure or
hepatocellular carcinoma over a period of 10–30 years [11].
Chronic HCV infection is one of the main causes of liver
cirrhosis and cancer [12,13] and >350 000 people die from
hepatitis C-related liver diseases every year. Moreover,
chronic HCV infection has been associated with several
extrahepatic diseases [14,15] including mixed cryoglobulina-
emia [16] and non-Hodgkin’s B-cell lymphoma [17].
Transmission of HCV occurs via direct parenteral exposure
to contaminated blood. HCV epidemiology has changed over
the last two decades: transfusion-associated transmission has
disappeared with the advent of serological tests based on the
detection of antibodies or HCV RNA. At present, a history of
intravenous drug injection represents the major risk factor for
newly acquired HCV infection (65%) [18], followed by sexual
(15%) [19] and occupational (4%) risks. Vertical transmission
occurs particularly in mothers with high viral load or who are
co-infected with human immunodeﬁciency virus (HIV) (<5%)
[20–22].
Do We Need a Preventive HCV Vaccine?
Despite a substantial decline in HCV transmission due to
improved prevention strategies and the introduction of new
powerful targeted therapies, hepatitis C remains a huge health
problem and there are several reasons for continuing to
pursue the objective of a vaccine. On the one hand, mortality
and morbidity due to HCV are not going to decrease. HCV has
surpassed HIV as a cause of mortality in the USA [23] and the
burden of HCV-related liver disease is projected to increase in
the next decade [24]. Indeed, the pool of asymptomatic
chronic HCV carriers who represent an infectious reservoir
will remain substantial for many years and c.50 000 new
infections still occur annually in the USA and Europe (CDC
data). On the other hand, therapeutic approaches to HCV
raise many concerns: current treatments, based on the IFN-a/
RBV backbone, are expensive, poorly tolerated and lead to
sustained virological response in about half of patients. New
directly acting antivirals that target speciﬁc HCV proteins are
emerging for the treatment of hepatitis C and results of
late-stage clinical trials with IFN-free combinations of directly
acting antivirals suggest that highly effective therapy to cure
HCV infection will be available in the near future [1]. However,
the very high costs make new antiviral therapy unlikely to be
sustainable for public health systems. Moreover, the treatment
rate is very low for HCV-infected patients. Indeed, <30% of
patients with chronic hepatitis C are aware of the infection and
only about 10% of patients are currently treated [25–27].
Therefore, even if new antivirals could cure 90% of patients
there would still be a considerable percentage of patients that
would be excluded.
An efﬁcient HCV vaccine would represent the most
cost-effective and realistic means to signiﬁcantly reduce the
worldwide mortality and morbidity associated with HCV
infection. An HCV vaccine would be initially indicated for
persons at risk of coming into contact with contaminated
blood, whereas a universal vaccination strategy could be
recommended later.
Is a Preventive HCV Vaccine Doable?
The observation that effective immune responses may occur
during the natural course of HCV infection supports the
feasibility of an effective vaccine. Indeed, in contrast to HIV
infection, a sizable proportion (20–35%) of infected persons
can clear the virus spontaneously. Generally, this is observed in
the ﬁrst 6–9 months of infection [28,29], and it has been
shown that individuals who have cleared infection are less
likely to develop chronic infection when re-exposed [30,31].
Collectively these data provide evidence that natural immunity
to HCV exists and that cross-protective immunity within and
between common HCV genotypes can be achieved.
Adaptive immunity is unequivocally mediated by one or
more of the following: neutralizing antibodies, CD4+
T-cell-mediated inﬂammation and CD8+ T-cell-mediated cyto-
toxicity. In the case of HCV, there is strong evidence that the
rapid induction of high-titre cross-neutralizing antibodies
targeting HCV envelope proteins correlates with viral clear-
ance and protects from re-infection [31–34]. On the other
hand, the importance of broad HCV-speciﬁc CD4+ T helper
and CD8+ cytotoxic responses in the resolution of infection
has been suggested by many studies [28,29,35–40]. Therefore,
an optimal HCV vaccine probably needs to elicit broad
cross-reactive cellular immune responses together with
cross-neutralizing antibodies.
As it is the development of chronic infection that causes
clinically evident disease, whereas acute infection is mostly
silent and without clinical consequences, an HCV vaccine that
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prevented chronic infection, allowing a self-limited acute
infection, would be acceptable.
Several vaccine strategies, listed in Table 1 and reviewed
elsewhere [41–43], have been explored to identify suitable
candidates, including subunit vaccines and genetic vaccines
(plasmid DNA and viral vector vaccines).
Promising results have been obtained with adjuvanted
recombinant gpE1/gpE2 heterodimer vaccine (Tables 2 and
3). When used to immunize naive chimpanzees that were then
challenged with a heterologous HCV strain, only one out of
nine developed chronic infection [44], whereas most control
animals became chronically infected following viral challenge.
Vaccination induced inﬂammatory CD4+ T-cell responses as
well as high titres of anti-gpE1/gpE2 antibodies capable of
blocking the binding to CD81, the main HCV receptor on
hepatocytes. Moreover, although immunization with polypep-
tide subunits does not result in direct stimulation of CD8+ T
cells, a high number of intrahepatic, HCV-speciﬁc CD8+
cytotoxic T lymphocytes secreting IFN-c was observed in
vaccinated chimps 10 weeks after the challenge, and the
percentage of these cells was inversely correlated with viral
loads [45]. However, not all animals with high anti-E1E2 titres
and/or high CD8+ T-cell activity were able to eradicate the
infection even though acute viraemia was suppressed. As the
result of encouraging preclinical results, the recombinant gpE1/
gpE2 heterodimer, formulated in an oil–water adjuvant MF59,
was among the earliest preventive vaccine candidates to enter
clinical trials. A phase I study has revealed that this vaccine is
safe and well tolerated and that it elicits anti-gpE1/gpE2
antibodies able to cross-neutralize major HCV genotypes and
CD4+ T-lymphocyte responses to HCV envelope proteins
(Table 3) [46,47].
It should be pointed out that the relevance of a humoral
response in resolving HCV infection is still controversial.
Anti-envelope antibodies are detected in nearly all chronically
infected patients but do not always have neutralizing proper-
ties. However, the advancements in design and selection of
immunogens may greatly improve the efﬁcacy of a vaccine
based on the elicitation of antibody response. For instance, it is
now possible to interrogate in great detail the B-cell repertoire
of HCV-infected patients, in particular those patients that have
cleared acute HCV infection, and to identiﬁy several HCV
cross-neutralizing antibodies that in turn could lead to the
identiﬁcation of E1E2 broadly neutralizing epitopes. This
approach may guide the structural design of novel E1E2
antigens with improved efﬁcacy. The same approach has been
extensively adopted in the HIV ﬁeld with impressive results,
and a few HCV broadly neutralizing antibodies have already
been described and reviewed [48].
T-cell-based vaccines have also been proposed as vaccine
candidates [43,49]. Adenoviral vectors are particularly attrac-
tive for this approach because they are the most potent at
T-cell priming in primates and humans [50]. The main
problem of adenoviral vectors is pre-existing immunity to
the vector, which can lead to its clearance before a response
is elicited to the inserted immunogen. However, this issue has
been overcome by using chimpanzee adenovirus as the gene
vehicle [51]. Good results in terms of elicitation of broad
CD4+ and CD8+ T-cell response in preclinical studies have
been obtained for one of these vaccines, consisting of a
chimpanzee adenoviral vector delivering non-structural genes
NS3–NS5B, which contain many well-deﬁned CD4+ and
CD8+ epitopes (Table 3). After heterologous viral challenge,
all animals became HCV-infected but those that were
vaccinated presented a 100 times lower average peak of
viraemia than controls. Moreover, three out of four chim-
panzees presented viraemia of short duration [52]. This
T-cell-based vaccine has been shown to be safe, well tolerated
TABLE 1. Clinical-stage vaccine candidates for hepatitis C virus (HCV)
Investigator Vaccine type Immunogen Stage Application
Chiron/Novartis
[46,62,63]
Recombinant
protein
Recombinant gpE1/gpE2 in
oil/water adjuvants
Phase 1 [46,63] Prophylactic vaccine
Okairos [64] Adenoviral
vector vaccine
Adenovirus vectors expressing
HCV NS 3, 4 and 5
Phase 2 Prophylactic/Immunotherapeutic
vaccine
Innogenetics/
GenImmune
[65]
Recombinant
protein
Alum-adjuvanted gpE1
glycoprotein
Phase 2 [66] Programme stopped
as no effects on viraemia or
ﬁbrosis progression
Immunotherapeutic vaccine
Intercell AG
(IC41) [67,68]
Peptide HCV peptide cocktail with
polyarginine
Phase 2 in combination with
pegylated interferon [69,70]
Immunotherapeutic vaccine
Globe Immune
(GI-5005)
Recombinant
yeast cells
Heat-killed yeast expressing
Core-NS3 fusion protein [71]
Phase 2 in combination with
pegylated interferon [72,73]
Immunotherapeutic vaccine
Tripep
(ChronVac-C)
Plasmid DNA DNA-based vaccination with
NS3/4A-expressing plasmid
Phase 1b Immunotherapeutic vaccine
CIGB-230 [74] Plasmid DNA and
recombinant
protein
Mixture of plasmid-expressing
HCV structural antigens with
a recombinant HCV
core protein
Phase 1b [75] Immunotherapeutic vaccine
Transgene
(TG4040)
Adenoviral vector
vaccine
Modiﬁed vaccinia Ankara virus
expressing NS proteins
(NS3-NS5B)
Phase 1 Immunotherapeutic vaccine
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and highly immunogenic in phase I studies and has now moved
to a phase II trial [53].
Overall, these results suggest that the goal of an effective
vaccine, protecting from different HCV strains and preventing
chronic infection, should be achievable and could be obtained
by strategies that combine the elicitation of broadly cross-neu-
tralizing antibodies with the induction of strong HCV-speciﬁc
T-cell responses.
Why Is It So Difﬁcult to Make One?
In contrast to another epidemic hepatotropic virus, hepatitis B
virus (HBV), for which a vaccine has been successfully
developed, a vaccine against HCV represents a signiﬁcant
challenge. Many viral and non-viral factors can be taken into
account to explain why it is so difﬁcult to develop an HCV
vaccine (Table 4).
Hepatitis C virus displays extremely high genetic diversity
(30% of nucleotide divergence between genotypes) compared
with HBV (8% divergence between different genotypes) [54].
HCV has evolved several effective immune escape strategies,
leading to a very high rate of chronic hepatitis following acute
infection (50–80%). Conversely, only 5–10% of immunocom-
petent adults develop chronic hepatitis after acute infection
with HBV [55]. The mechanisms of HCV evasion from the host
immune system affect both innate and adaptive immune
responses. Evasion from the innate immune system includes
impairment of dendritic and natural killer cell responses and
TABLE 3. Summary of main results obtained for adjuvanted gpE1/gpE2 heterodimer vaccine and for NS3-5B adenoviral vaccine
Vaccine Vaccine type Study type Description Status Main results Elicited immune response
Chiron corp gpE1/gpE2
Heterodimer
Subunit vaccine Preclinical Prophylactic efﬁcacy in
Chimpanzee model
Completed Protection from chronic
hepatitis after challenge
with homologous and
heterologous strain
High titres of anti-E1E2 nAb,
which correlate inversely with
viral titres; hepatitis C virus
(HCV) speciﬁc CD4+ T-cell
response
Phase I Blinded randomized
dose-ranging study in
60 healthy volunteers
Completed Satisfactory safety and
tolerability
Anti-E1E2 antibodies able to
cross-neutralize major HCV
genotypes with titres between
100 and 2000 (protected chimps
range); very strong CD4+ T-cell
responses to E1E2
Phase II Proof-of-concept ﬁeld
trial in high-risk subjects
Stopped at
planning stage
Okairos NS3-5B Adenoviral vector
vaccine
Pre-clinical Prophylactic efﬁcacy in
Chimpanzee model
Completed Amelioration of acute
hepatitis and acute
viraemia in vaccinees
after challenge with
heterologous strain.
No signiﬁcant difference
in carrier rates between
vaccinees and controls
Broad CD4+ and CD8+ T
lymphocytes
Phase I Blinded randomized study
in 40 healthy volunteers
Completed Safe and highly
immunogenic
Broad CD4+ and CD8+ T
lymphocytes secreting multiple
cytokines (interleukin-2,
interferon-c, tumour necrosis
factor-a) targeting multiple
epitopes and recognizing
heterologous strains. Presence
of polyfunctional and proliferative
long-term memory population
after 1 year
Phase I/II Randomized, double-blind,
placebo control in
intravenous drug user
population; (Phase I:
68 volunteers; Phase II:
276 additional volunteers)
Ongoing (results
expected in
2015/2016)
TABLE 2. Outcome of chimpanzee vaccination/challenge
studies performed with adjuvanted recombinant gpE1/gpE2
formulations
gpE1/gpE2
Unimmunized
control
Statistical
signiﬁcanceb (p)
Homologous challenge
Acute infections 7/12a 10/10
Chronic infections (%) 2/12 (17) 7/10 (70) 0.03
Heterologous challenge
Acute infections 9/9 14/14
Chronic infections (%) 1/9 (11) 8/14 (57) 0.04
Total
Acute infections 16/21 24/24
Chronic infections (%) 3/21 (14) 15/24 (63) 0.002
Animals were immunized with 30–80 lg gpE1/gpE2 in various oil/water adjuvants
on months 0, 1 and 6 approximately, followed by intravenous challenge 2–4 weeks
later with hepatitis C virus 1 (HCV-1) or HCV-H. Both strains belong to the 1a
subtype. Circulating levels of viraemia were measured using RT-PCR assays for
HCV genomic RNA for at least 1 year post-challenge.
Adapted from reference [44].
aIn ﬁve vaccinees challenged with homologous HCV-1, no viraemia could be
detected at any time after challenge in either plasma peripheral blood mononu-
clear cells or liver biopsy samples and so were considered to have been sterilized.
bp-values (Fishers exact test) refer to chronic carrier rates between controls and
vaccinees.
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reduction of type-I IFN induction [56–59]. Among the mech-
anisms used to escape from the adaptive immune response, of
crucial importance are the continuous generation of new viral
variants occurring during HCV infection, allowing the virus to
escape the action of HCV-speciﬁc CD8+ T cells and neutralizing
antibodies, and the exhaustion of CD8+ T cells observed during
chronic infections, which leads to a reduced ability both to
secrete antiviral cytokines (including IFN-c) and to proliferate in
response to antigen stimulation [56]. Another evasion mech-
anism is the ability of HCV to be transferred to naive cells
through direct cell–cell contact in a CD81-independent way, so
avoiding the effect of neutralizing antibodies [60]. Finally, single
point mutations, glycosylation site modiﬁcations and confor-
mational changes occur in HCV glycoproteins during HCV
evolution and contribute to the virus’ adaptation to humoral
pressure. Conversely, the HBV envelope protein (i.e. the
hepatitis B surface antigen, or HBsAg), is highly conserved and
undergoes minor post-translational modiﬁcation.
Apart from these intrinsic obstacles, the exact correlate of
immune protection against HCV infection has not been
identiﬁed, possibly because of the heterogeneity contained
within small study populations of patients together with the
limitations in terms of animal models of HCV infection.
The planning and execution of clinical trials for efﬁcacy
assessment pose many questions as well. Because of the
relatively low incidence of new infections in the developed
world, it is not trivial to identify the appropriate at-risk
population to enrol. Post-transfusion infection risk has been
eliminated by donor screening, and other high-risk groups
suitable for efﬁcacy testing can have inherent difﬁculties such as
lack of compliance (in intravenous drug users), low incidence of
infection (healthcare workers), lack of supporting infrastruc-
ture (in many developing countries where incidence of infection
is high) and ethical issues (in prisoner populations where
prevalence and incidence of infection are both high). However,
some of these cohorts have been used successfully for testing
HBV vaccine, and so these obstacles should not be insuperable.
As discussed above, in the case of HCV, a vaccine that
allowed only a ‘transient infection’, while preventing the
development of chronic HCV infection, would be as beneﬁcial
as one that provided sterilizing immunity. However, the design
of an efﬁcacy trial intended to measure prevention of chronic
infection is not straightforward, in particular in the absence of
a strong correlate of immunity. In fact, studies on patients with
acute hepatitis C have shown that HCV infections treated with
pegylated IFN-a during the acute phase are eradicated in
virtually all patients [61]. As the chronic state of the infection is
deﬁned starting from 6 months after onset, it becomes very
difﬁcult to conclude an efﬁcacy trial. When an infected
vaccinee is detected, IFN treatment will have to be started
without delay and it will be impossible to establish whether the
infection will become chronic. For this reason, for example, a
phase II, proof-of-concept trial with adjuvanted E1/E2 hetero-
dimer was stopped at planning stage.
Finally, developmental issues exist for gpE1/gpE2 vaccine.
Indeed, the heterodimer has to be puriﬁed as intracellular
material from endoplasmic reticulum of mammalian cells,
making it very difﬁcult to scale up its production.
Conclusions
Only a few years ago, the prospects for effective vaccination
against HCV were considered remote. The situation today is
more optimistic for several reasons. First, we now know that
the spontaneous eradication of virus occurs in a consistent
fraction of acute infections and is associated with speciﬁc
immune responses to the virus. Second, clear evidence
TABLE 4. Summary of the main obstacles to the development of an effective hepatitis C virus (HCV) vaccine as compared to the
successfully developed hepatitis B virus (HBV) vaccine
HCV HBV
Viral factors High rate of development of chronic infection following
asymptomatic acute infection in most immunocompetent hosts;
High genetic variability between different genotypes (30–35%);
High variability and heavy N-glycosylation of external proteins;
Several mechanisms of evasion from host innate and adaptive
immune system evolved
Asymptomatic or clinical acute infection with rare chronic infection development
in most immunocompetent hosts; Low genetic variability between different
genotypes (8%); The envelope protein (hepatitis B surface antigen) is very
conserved and have minor post translational modiﬁcations
Efﬁcacy assessment
factors
No clear correlate of protection identiﬁed; No simple cohort
available for efﬁcacy trials; No immunocompetent small animal
model available; Prevention of chronic infection is technically
difﬁcult to assess
Neutralizing antibodies represent correlate of protection; Efﬁcacy trials relatively
easy and doable in high incidence populations at time of vaccine development
Technical issues The glycoproteins E1/E2 are very complex to scale up, because
they have to be puriﬁed as intracellular material from the
endoplasmic reticulum of mammalian cells
Recombinant hepatitis B surface antigen is easily produced in yeast cells
Other factors The myth has been spread that HCV will disappear in a few years
and that in any case new antiviral agents will ﬁnish the job; as a
result there private or public investments in the HCV vaccine
ﬁeld are scarce
Vaccine still under development Highly efﬁcacious vaccine available (estimated >1 000 000 deaths prevented
worldwide)
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indicates that, despite the high percentage of chronic HCV
infections, the immune system is capable of a response that
leads to HCV clearance and protection against re-infection.
In light of this, several efforts have been made to identify
and develop vaccine candidates recapitulating these immune
responses. Some of these candidates have given promising
results in the chimpanzee model of infection and have
subsequently moved to clinical trials. However, many issues
still remain to be resolved before a vaccine against HCV can be
achieved. A clear correlate of protection has not yet been
identiﬁed. Moreover, not only is it difﬁcult to identify the
appropriate at-risk population to enrol in an efﬁcacy trial for a
preventive HCV vaccine, but it may also be very difﬁcult to
conclude an efﬁcacy trial designed to measure prevention of
chronic infection. If these obstacles are removed, the prospect
of a vaccine appears a realistic objective for the near future.
Considering that HCV is the ﬁrst cause of primary liver cancer,
this would mean that an important cause of global morbidity
and mortality would be controlled.
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